Verona Pharma plc (VRNA) is a publicly traded company in the Unknown sector. Across all available filings, 19 corporate insiders have executed 271 transactions totaling $327.6M, demonstrating a bearish sentiment with -$314.1M in net insider flow. The most recent transaction on Oct 7, 2025 involved a transaction of 64,072 shares valued at $0.
No significant insider buying has been recorded for VRNA in the recent period.
No significant insider selling has been recorded for VRNA in the recent period.
Based on recent SEC filings, insider sentiment for VRNA is bearish with an Insider Alignment Score of 2/100 and a net flow of -$314.1M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Verona Pharma plc (VRNA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 19 insiders are actively trading VRNA stock, having executed 271 transactions in the past 90 days. The most active insider is Rishi Gupta (Executive), who has made 9 transactions totaling $145.9M.
Get notified when executives and directors at VRNA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Oct 7, 2025 | Ackermann Christina | Executive | Disposition | 64,072 | $N/A | $0 | |
| Oct 7, 2025 | Ackermann Christina | Executive | Disposition | 72,000 | $N/A | $0 | |
| Oct 7, 2025 | Ackermann Christina | Executive | Option Exercise | 72,000 | $N/A | $0 | |
| Oct 7, 2025 | Cunningham Kenneth | Executive | Disposition | 72,000 | $N/A | $0 | |
| Oct 7, 2025 | Cunningham Kenneth | Executive | Option Exercise | 72,000 | $N/A | $0 | |
| Oct 7, 2025 | Cunningham Kenneth | Executive | Disposition | 79,776 | $N/A | $0 | |
| Oct 7, 2025 | Aloysius Brady James | Executive | Option Exercise | 72,000 | $N/A | $0 | |
| Oct 7, 2025 | Aloysius Brady James | Executive | Disposition | 72,000 | $N/A | $0 | |
| Oct 7, 2025 | Aloysius Brady James | Executive | Disposition | 23,176 | $N/A | $0 | |
| Oct 7, 2025 | Edwards Martin | Executive | Option Exercise | 72,000 | $N/A | $0 | |
| Oct 7, 2025 | Edwards Martin | Executive | Disposition | 72,000 | $N/A | $0 | |
| Oct 7, 2025 | Edwards Martin | Executive | Disposition | 157,992 | $N/A | $0 | |
| Oct 7, 2025 | R. Ebsworth David | Executive | Disposition | 880,499 | $N/A | $0 | |
| Oct 7, 2025 | R. Ebsworth David | Executive | Disposition | 617,600 | $N/A | $0 | |
| Oct 7, 2025 | R. Ebsworth David | Executive | Disposition | 72,000 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 116 | $320.9M | 91.9% |
Payment(F) | 47 | $21.1M | 6.0% |
Purchase(P) | 4 | $6.8M | 1.9% |
Award(A) | 16 | $351.2K | 0.1% |
Disposition(D) | 29 | $0 | 0.0% |
Exercise(M) | 36 | $0 | 0.0% |
Gift(G) | 23 | $0 | 0.0% |
Insider selling pressure at Verona Pharma plc has increased, with 19 insiders executing 271 transactions across all time. Total sales of $320.9M significantly outpace purchases of $6.8M, resulting in a net outflow of $314.1M. This selling activity appears largely discretionary, which may warrant closer attention from investors.